ArticleMedical oncology (Northwood, London, England)2011
Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report.
Article in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Case report: Complete response after transcatheter arterial chemoembolization combined with donafenib plus tislelizumab therapy for hepatocellular carcinoma with main trunk portal vein tumor thrombus in a patient coinfected with HIV and HBV.Frontiers in immunology · 2024Article
- Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV.Infectious disease reports · 2022Review
- A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario.Journal of hepatocellular carcinoma · 2021Review
- Diffuse advanced hepatocellular carcinoma after HCV eradication in an HIV-infected patient: A unique complete response to sorafenib.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020Article
- Review
- Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review.Clinical and molecular hepatology · 2017Review
- A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.The oncologist · 2017Article
- Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.BMC gastroenterology · 2017Review
- Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib.Journal of gastrointestinal oncology · 2016Article
- Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.Clinical and molecular hepatology · 2015Article
- Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.European journal of medical research · 2015Review
- Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review.World journal of gastroenterology · 2014Review
- Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib.OncoTargets and therapy · 2014Article
- Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy.Digestive diseases and sciences · 2013Article
- Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma.Oncology letters · 2013Article
- Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report.World journal of gastrointestinal oncology · 2013Article
- Treatment of Recurrent Hepatocellular Carcinoma with Sorafenib in a HIV/HCV Co-Infected patient in HAART: A Case Report.Infectious agents and cancer · 2012Article
- Complete response after short-term sorafenib treatment in a patient with lymph node metastasis of hepatocellular carcinoma.Case reports in oncology · 2012Article
- Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.Medical molecular morphology · 2011Review
- Hepatocellular Carcinoma with Distant Metastasis Cured by 20-Day Sorafenib Treatment.Case reports in gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A significant proportion of HIV patients, ranging between 5-67%, are co-infected with hepatitis B virus (HBV). Several studies suggest an increasing incidence of hepatocellular carcinoma (HCC) in HIV infected individuals. We report the case of a 69 years old male co infected with HBV and HIV who developed HCC. The patient was unfit for curative approach and he underwent three sessions of transcatheter arterial chemoembolisation (TACE). After the last session the disease assessment showed progression and sorafenib therapy was initiated. Highly active antiretroviral therapy (HAART) was continued during sorafenib treatment. The patient achieved a radiological complete response (CR) after 6 months of therapy and remained with no sign of HCC progression at subsequent assessment. Meanwhile, patient's HIV and HBV infections remained stable. Regarding toxicity the patient developed grade 3 hand foot skin reaction (HFSR) that required 50% dose reduction of sorafenib, grade 3 hypertension and grade 2 diarrhea. In conclusion this is the first case of successful treatment of HCC in a HIV-HBV co-infected patient and only the second report of the co administration of sorafenib with HAART.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.